{
    "2018-12-12": [
        [
            {
                "time": "2019-01-01",
                "original_text": "Pharma Stocks That Could Cure Ailing Portfolios in 2019",
                "features": {
                    "keywords": [
                        "pharma",
                        "cure",
                        "portfolios"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "Why Neurocrine Biosciences Is Tanking",
                "features": {
                    "keywords": [
                        "neurocrine",
                        "biosciences",
                        "tanking"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS",
                "features": {
                    "keywords": [
                        "etf",
                        "outflow",
                        "xlv",
                        "abbv",
                        "abt",
                        "cvs"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019",
                "features": {
                    "keywords": [
                        "biotech",
                        "bounce back"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "Mavyret Is a Leading Drug in AbbVieâ€™s HCV Franchise",
                "features": {
                    "keywords": [
                        "mavyret",
                        "leading drug",
                        "abbvie",
                        "hcv"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "AbbVie - High Yield at a Low Valuation",
                "features": {
                    "keywords": [
                        "abbvie",
                        "high yield",
                        "low valuation"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}